Cost-effectiveness analysis of pharmaceutical and other treatments for children with autism spectrum disorders (ASDs) has the potential to improve access to services by demonstrating the value of treatment to public and private payers, but methods for measuring QALYs in children are under-studied. No cost-effectiveness analyses have been undertaken in this population using the cost-per-QALY metric.

, , ,
Erasmus School of Health Policy & Management (ESHPM)

Tilford, J. M., Payakachat, N., Kovacs, E., Pyne, J., Brouwer, W., Nick, T., … Kuhlthau, K. (2012). Preference-Based Health-Related Quality-of-Life Outcomes in Children with Autism Spectrum Disorders: A Comparison of Generic Instruments. PharmacoEconomics, 30(8), 661–679. Retrieved from